Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Perry who wrote (2072)	5/5/1998 3:58:00 PM
From: Richard Ogier	Respond to of 9523

Perry, I totally agree with you. Analyzer's estimate of $6 billion in sales from 2001 to 2009 is probably way low. That might be a good estimate for the US, but IMO worldwide sales will be more than twice that. Moreover, if they get the patent extended for another 20 years... Richard

To: Perry who wrote (2072)	5/6/1998 4:25:00 AM
From: Z Analyzer	Read Replies (2) \| Respond to of 9523

<<With all due respect I'll stick with my brokers analysis that clearly points out that valuations for PFE is not excessive based on the P/E premium. However, like I said we'll know in a few months who is right.>> Wonder if you could share that analysis with us and tell us which firm? Actually it will be a few years before anybody knows who is right. In several months, someone may just think they are right. And my numbers used $10 bil in sales. To put that in perspective, the worlds largest brewer, Anhauser -Busch is in that ballpark. What I don't understand is why analysts generally continue to use such low numbers for annual sales.